Photo courtesy of James Pursey/EGPAF

As part of our ongoing commitment to deliver innovation in the areas of highest unmet need, we have created the £10 million Paediatric Innovation Seed Fund.

Around 3.4 million children are living with HIV worldwide but 72% of those needing treatment do not have access to appropriate care and medicines. Among several barriers preventing further scale-up of the numbers of children on treatment is the lack of low-cost medicines that are palatable and acceptable for use by children. 

The seed fund specifically supports partnerships that focus on expanding the evidence base for paediatric care and treatment and the development of paediatric fixed-dose combination (FDC) medicines. These include:

  • Our non-monetary Memorandum of Understanding with the Clinton Health Access Initiative (CHAI) to develop an affordable taste-masked combination medicine for children living with HIV in developing countries. 
  • Our unrestricted grant to the International AIDS Society (IAS) CIPHER research programme aimed at answering outstanding clinical and operational research questions needed to optimise clinical management and delivery of HIV services for infants, children and adolescents. 
  • Our partnership with the Elizabeth Glaser Pediatric AIDS Foundation to increase early detection and access to antiretroviral therapy for HIV-positive infants and young children in Africa and to strengthen leadership and policies around paediatric HIV/AIDS. 
  • Our collaboration with amfAR TREAT Asia to improve the quality of healthcare for infants and children living with HIV across Asia through clinical data collection.
  • Our support for the JUSTRI Training Resource Initiative which partners experts in Romania, UK and Eastern Europe to coordinate an observational, cross-sectional and longitudinal follow up study of children living with HIV
  • Our support for a Mater Misericordiae University Hospital observational cross-sectional two year study of 2,000 HIV infected children; 1,500 of whom are currently treated at outpatient clinics in the city of East London, Eastern Cape Province of South Africa.